JP2025505578A - Ｔ型カルシウムチャネル調節因子を使用した治療方法 - Google Patents

Ｔ型カルシウムチャネル調節因子を使用した治療方法 Download PDF

Info

Publication number
JP2025505578A
JP2025505578A JP2024545928A JP2024545928A JP2025505578A JP 2025505578 A JP2025505578 A JP 2025505578A JP 2024545928 A JP2024545928 A JP 2024545928A JP 2024545928 A JP2024545928 A JP 2024545928A JP 2025505578 A JP2025505578 A JP 2025505578A
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
compound
formula
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505578A5 (https=
Inventor
バーナード ラヴィーナ，
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2025505578A publication Critical patent/JP2025505578A/ja
Publication of JP2025505578A5 publication Critical patent/JP2025505578A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024545928A 2022-02-03 2023-02-03 Ｔ型カルシウムチャネル調節因子を使用した治療方法 Pending JP2025505578A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306340P 2022-02-03 2022-02-03
US63/306,340 2022-02-03
PCT/US2023/061973 WO2023150703A2 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Publications (2)

Publication Number Publication Date
JP2025505578A true JP2025505578A (ja) 2025-02-28
JP2025505578A5 JP2025505578A5 (https=) 2026-02-12

Family

ID=87552982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545928A Pending JP2025505578A (ja) 2022-02-03 2023-02-03 Ｔ型カルシウムチャネル調節因子を使用した治療方法

Country Status (10)

Country Link
US (1) US20250170114A1 (https=)
EP (1) EP4472633A4 (https=)
JP (1) JP2025505578A (https=)
KR (1) KR20240144291A (https=)
CN (1) CN118785905A (https=)
AU (1) AU2023216271A1 (https=)
CA (1) CA3243616A1 (https=)
IL (1) IL314576A (https=)
MX (1) MX2024009559A (https=)
WO (1) WO2023150703A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500340A (ja) * 2005-06-29 2009-01-08 メルク エンド カムパニー インコーポレーテッド ４−フルオロ−ピペリジンｔ型カルシウムチャネルアンタゴニスト
EP3340988B1 (en) * 2015-11-12 2025-04-09 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
IL297642A (en) * 2020-04-29 2022-12-01 Praxis Prec Medicines Inc Methods for using t-type calcium channel modulators
US20240025852A1 (en) * 2020-11-09 2024-01-25 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
EP4472633A2 (en) 2024-12-11
US20250170114A1 (en) 2025-05-29
CA3243616A1 (en) 2023-08-10
EP4472633A4 (en) 2026-01-14
WO2023150703A2 (en) 2023-08-10
AU2023216271A1 (en) 2024-08-15
CN118785905A (zh) 2024-10-15
MX2024009559A (es) 2024-09-23
WO2023150703A3 (en) 2023-09-14
KR20240144291A (ko) 2024-10-02
IL314576A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
US20230165847A1 (en) Methods of use of t-type calcium channel modulators
JP2019524834A (ja) ビグアナイド系による発達障害の治療方法
CN102143687B (zh) 4-氨基吡啶在改善具有脱髓鞘和其它神经系统状况的患者的神经-认知和/或神经-精神病学损伤中的用途
JP2019535760A (ja) フルピルチンを用いた発達障害および／または発作性障害の処置方法
JP2017518330A (ja) 大うつ病性障害（ｍｄｄ）の治療のためのプロトコル
US20250295646A1 (en) Methods of use of t-type calcium channel modulators
JP2025505578A (ja) Ｔ型カルシウムチャネル調節因子を使用した治療方法
TWI892226B (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
JP2026507197A (ja) 本態性振戦の治療方法
JP2022506019A (ja) 高用量の放出調節フペルジン製剤の使用
JP2026507195A (ja) 高用量単回投与製剤及びその使用の方法
WO2025188619A1 (en) Methods of treating parkinson's disease with t-type calcium channel modulators

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260203